Business

Biotrin assay to monitor cervical cancer exposure rates

Article Abstract:

Dublin-based Biotrin's immunoassays can be used to guarantee the integrity of the cervical cancer immunization programs by using either Gardasil or Cervarix, which are recombinant vaccines against multiple subtypes of human papilloma virus (HPV). Biotrin has licensed the technology from the U.S. National Cancer Institute (NCI) and it aims to use the assays to track the effectiveness of immunization programs.

Fast track to MS drug

Article Abstract:

The launch of the humanized monoclonal antibody Antegren developed by Biogen Idec of Cambridge, Massachusetts, and Elan of Dublin as a treatment for multiple sclerosis is poised to shake the market now dominated by a handful of products. The issue, whether the new multiple sclerosis drug Antegran would be the next blockbluster drug, as predicted by some analysts is discussed.

Production technologies change flu vaccine landscape

Article Abstract:

The sanction of the first seasonal influenza vaccine based on mammalian cell culture in the European Union, represents the start of technological transition from the 50-year old, egg-based manufacturing procedure in the industry.